Plexiform neurofibromas (PNF) are benign, often infiltrative tumours of the peripheral nerve sheath classically linked to ...

Poolbeg Pharma has announced that the European Patent Office has granted its European Immunomodulator II patent application ...

The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research -- -- The Hoffman ALS ...

The FDA approved an oral therapeutic for adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform ...

November 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the ...

The Food and Drug Administration (FDA) has approved Koselugo ® (selumetinib) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Previously, ...

Smart multi-target drugs are redefining how we treat complex diseases by combining AI-driven discovery with mechanistic ...

The US Food and Drug Administration has approved the expanded usage of AstraZeneca's Koselugo drug to adults with neurofibromatosis type 1 (NF1) – a rare, progressive, genetic condition that can ...

By Dr. Priyom Bose, Ph.D. Study: From obesity to cancer: Gut microbiome mechanisms, biomarkers, and U.S. public health ...

Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein ( GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased ...

In an effort to reveal the inner workings of a protein that serves as a cell's damage detection system, scientists at Johns ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on ...